Active substance: Elemental iron
Form: ampoules Solution for injection or concentrate for solution for infusion.
Dosage: 100 mg elemental iron per ampule of 5 ml
packaging: Box 5 ampoules.
Target: patients suffering from iron deficiency with or without anaemia when oral treatment is not possible or is less effective
Amifer IV is indicated for the treatment of iron deficiency in the following indications:
Base: The total cumulative dose of Amifer IV, equivalent to the total iron deficit (mg), is determined by the haemoglobin level (Hb) and body weight (BW). The dose of Amifer IV must be individually calculated for each patient according to the total iron deficit calculated with the following Ganzoni formula
Total amount of Amifer IV (20 mg of iron per ml) to be administered is equivalent to the total Iron deficit (mg) devides by 20 mg/ml
Simplified method
Amifer IV should only be given intravenously.
This may be
– slow intravenous injection (bolus at a rate of 1 ml per minute)
– a drip infusion (diluted only in saline)
– or an injection directly into the venous line of a dialysis machine.
It is recommended not to exceed 200 mg of Amifer IV per day and this 1 to 3 times per week (max 1 day out of 2) ou d’une injection effectuée directement dans la ligne veineuse d’un générateur de dialyse.
Over-the-counter drug
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma